Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026)

Jazz Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $2.2 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 83.75% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (up 83.75% YoY), while the FY2025 annual figure was $2.2 billion, up 115.92% from the prior year.
• Total Current Liabilities was $2.2 billion for Q1 2026 at Jazz Pharmaceuticals, roughly flat from $2.2 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $2.3 billion in Q3 2025 to a low of $705.4 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities sank 34.54% in 2024, then soared 120.79% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $933.2 million in 2022, then surged by 64.67% to $1.5 billion in 2023, then plunged by 32.42% to $1.0 billion in 2024, then jumped by 115.92% to $2.2 billion in 2025, then rose by 0.18% to $2.2 billion in 2026.
• The last three Total Current Liabilities figures came in at $2.2 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.